HENDERSON, NV -- (Marketwired) -- 01/20/15 -- United Health Products Inc. (OTCQB: UEEC) announced that it has received formal results of recent tests performed at Spring Valley Laboratories, a GLP compliant CRO laboratory. These tests were performed on pigs that had their femoral arteries exposed. A 5 millimeter puncture wound was established and the arterial tissue removed, creating a hole in the femoral artery. The arterial bleeding was allowed for a 45 second interval prior to any HemoStyp® gauze being applied under constant pressure. Fluid was administered to the pig through a catheter placed in the neck to replace any blood loss through the wound site. The administered fluids consisting of .9 % sterile crystalloid fluids further diluted the blood and created extreme pressure at the wound site.
The test on the non-control pigs began with examining how much material was best administrated to control arterial bleeding. The first two subjects showed that HemoStyp® was far more effective when using less material than first assumed. Once the effective amount was determined, two subjects achieved successful hemostasis in an average time of 36 minutes. In accordance with test protocol, the subjects were monitored for up to 180 minutes to substantiate baseline vitals were achieved and maintained. The next closest competitive product tested in a similar manner demonstrated an average time of hemostasis in 63 minutes.
Douglas Beplate, CEO of United Health Products, commented, "We feel these results are remarkable because we were repeatedly, demonstrating and achieving complete hemostasis in a significantly faster time than products that were previously tested. More importantly, we were able to achieve this milestone with an all-natural, absorbable product. Management intends to incorporate these findings to further improve usage protocols and promote our products for their demonstrated superior benefits."
About United Health Products Inc.
United Health Products Inc. (UEEC) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural, and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UEEC is focused on identifying new markets and applications for its product as well as ramping up sales in its current markets. For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
United Health Products Inc.
IR & Media Contact:
PCG Advisory Group
Managing Director PR
+1 646 683 8998